On November 7, DexCom fell 5.09% in Regular Trading, trading at $80.21, with turnover of $92.48 million.
The most relevant recent catalyst in public information is that the stock had rallied after stronger-than-expected third-quarter results and a higher full-year revenue outlook, and the current move indicates that those post-earnings gains are continuing to unwind.
DexCom previously reported third-quarter adjusted EPS of $0.73, above the $0.67 consensus, on revenue of $1.344 billion, ahead of the $1.327 billion expectation. The company also raised its full-year revenue guidance to $5.20 billion-$5.25 billion from $5.18 billion-$5.25 billion. A later analyst note said the results and guidance pointed to stronger momentum into next year, supported by U.S. share gains, near-record global new-patient additions, and ongoing conversion to the 15-day G7 sensor.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments